Insilico Medicine secured inclusion in the Hang Seng Composite Index, signaling wider investor access to a clinical‑stage AI‑driven biotech and strengthening its market profile. The listing will increase institutional visibility and potentially broaden capital access via Stock Connect eligibility. Separately, a collaboration between OpenAI and Ginkgo Bioworks demonstrated how generative AI paired with autonomous lab platforms can design and iterate biological experiments faster than traditional workflows, accelerating the experimental cycle. Together these developments reflect mounting industry momentum for AI to compress discovery timelines and reshape R&D execution.